RxDoctor Payments Data

Mark Cohen, MD

Neurology · Brooklyn, NYNPI 1609371145

Payments from drug & device makers

$3,936in general payments, 2019–2025

Across 125 payments — averaging $31.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$944
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$456
  • Nevro Corp.$419
  • AbbVie$300
  • Valinor Pharma, LLC$290
  • Galderma Laboratories, L.p.$235
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$74319%
  • Food & beverage$3,19281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,936 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$115,309
Medicare patients
331
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate12$23,410
QuliptaAtogepant17$18,272
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen55$5,290
Diclofenac Sodium22$3,113
Lidocaine12$1,446
Doxepin Hcl12$1,057
Celecoxib33$746
Gabapentin79$740
Pregabalin31$527
Tizanidine Hcl28$426
Oxycodone Hcl18$260
Baclofen26$180
Tramadol Hcl17$117
Cyclobenzaprine Hcl14$101
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$219$23,41012 claims
AbbVieQulipta$300$18,27217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,623 neurology providers in New York.

Other neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →